UnionClin to Showcase CGT Clinical Trial Expertise at VBEF 2025 Forum
Top 100 Future Healthcare and Pharmaceutical Exhibition
Innovative Assets, Driving New Growth for a Healthy China.
Looking for innovative assets and products? Start with VCBeat VBEF!
Meeting Background
In the first quarter of 2025, Chinese biopharmaceutical companies announced 33 cross-border collaborations, with the total disclosed transaction value surpassing the $36.2 billion mark. This burgeoning wave of global expansion not only showcases the concentrated strength of independent innovation among Chinese biotech firms but also vividly reflects the restructuring of the global pharmaceutical industry landscape. Transitioning from passive licensing-out to proactive co-innovation through NewCo models, domestic enterprises are breaking through industrial barriers via diversified cooperation strategies and charting new courses for international expansion.
The “2025 VBEF Top 100 Future Healthcare & Pharma Exhibition,” hosted by VCBeat, will grandly open at the Suzhou International Expo Center on May 9–10. As one of the core forums of the exhibition, the “CGT Venture Capital and BD New Opportunities Forum” (Forum Area A105) will focus on R&D breakthroughs, industrial synergy, and commercialization challenges in the field of cell and gene therapy (CGT). It will conduct in-depth discussions on topics including full lifecycle management of innovative drugs, achievement transformation and ecosystem co-construction, and the global expansion of CGT products and industry chains.
Dr. Han Haixiong, Chief Medical Officer of Youlin Medicine, has been invited to attend and will deliver a keynote speech titled “Breakthroughs and Challenges: Core Elements in the Design and Execution of Clinical Trials for Novel CGT Drugs” from 10:30 to 11:00 on May 10. The global cell and gene therapy (CGT) sector is experiencing explosive growth, with CAR-T therapy sales surpassing $4.4 billion in 2024, while Chinese companies are accelerating breakthroughs in areas such as gene editing and universal cell therapies. Nevertheless, high clinical trial costs, complex regulatory requirements, and homogeneous competition remain significant pain points for the industry. Drawing on Youlin Medicine’s experience in the clinical development of innovative CGT drugs, Dr. Han will analyze how innovative trial designs can accelerate drug approval while addressing challenges such as patient recruitment, data integration, and long-term follow-up, engaging in in-depth dialogue with industry peers.
Speaker Background
Dr. Haixiong Han
Personal Profile:
Time: 2025/5/10 10:30-11:00
Subject:"Breakthroughs and Challenges: Core Elements in the Design and Execution of Clinical Trials for New CGT Drugs"
Challenges and Responses
“Going Global” Is Inevitable, Yet the Deep Waters Are Rife with Hidden Reefs—Only by Anchoring in Innovation and Steering with Compliance Can Companies Navigate the Global Course Amidst Intertwined Technical Barriers and Market Cycles. Leveraging its international clinical research team and cost-effective services, Youlin Medicine is accelerating its integration into the global pharmaceutical industry chain. By delivering high-quality solutions such as simultaneous China-US regulatory filings, innovative trial designs, and global clinical data management, the company has established a two-way channel for international multi-center clinical studies and local clinical development, simultaneously driving the introduction of overseas products into China and the global expansion of domestic innovative therapies.
Suzhou International Expo Center
- CGT Venture Capital & BD New Opportunities Forum (Forum Area 1, A105)
The Future Healthcare and Pharmaceutical Top 100 Exhibition (VBEF) isHosted by VCBeatThe largest and most information-rich industry summit in China's medical and health innovation sector, aiming to gather core industry forces, drive transformation in the innovative healthcare industry, and build a communication and matchmaking platform for the entire medical and health industry chain.
After eight editions, VBEF hasSeizing the Opportunity of the Release of the “Top 100 Future Healthcare Companies” List, bringing together the most dynamic innovative enterprises, high-growth companies, industry leaders, medical institutions, financial capital, and upstream and downstream supply chains from both China and abroad, to comprehensively showcase the year’s new technologies, products, services, resources, business opportunities, and ecosystem developments, gradually building a“Find innovative assets and products at VBEF”brand label, becoming a bellwether for industrial investment, business development (BD), and market collaboration in that year and the period to follow.
2025 VBEF “THE NOW: Tipping Point” as the conference theme, with innovative exhibitions and in-depth networking at its core, featuring"Forum + Awards + Exhibition + Report + Resource Matchmaking": Five Major Sections, continuously providing new channel expansion opportunities for innovative products, and delivering ecosystem collaboration value to various institutions through investment and financing, business development (BD) partnerships, supply chain transactions, and overseas expansion.